EVP R&D Raheja purchases 20,000 shares in 2 tranches at $2.72 and $2.60 while stock down 71.1% from 52-week high
Raheja Manohar K. made 2 separate purchases totaling 20,000 shares for $53,250.00 ($53.2K) at an average price of $2.66, increasing his holdings by 14.8% to 155,000 shares. The current stock price of $2.40 sits -71.1% below the 52-week high of $8.31, with the stock having declined 9.8% over 30 days and 33.0% over 90 days. Raheja's prior trades at SGHT show a consistent pattern of poor timing: his 4 preceding buys at this ticker (December 6, December 3, November 29, and November 19) each generated negative 90-day returns ranging from -26.0% to -35.5%, with a 0% win rate. His cross-ticker track record is similarly weak, with 4 prior buys averaging -32.6% 90-day returns and 0% win rate. The company is unprofitable, with net income of $-11.1M on revenue of $20.2M, and recorded negative annual revenue growth of -1.5%.
EVP R&D buys 5,000 SGHT shares at $3.85; third purchase in 18 days amid -37.7% 90-day decline
Raheja Manohar K., EVP of Research & Development, purchased 5,000 shares of Sight Sciences at $3.85 on 2024-12-06, increasing his holdings to 111,000 shares. This is the third open-market purchase by this executive in the past 18 days (prior buys on 2024-12-03 and 2024-11-29), establishing a clear pattern of accumulation. The timing context is notable: the stock has declined -37.7% over the past 90 days and stands -52.0% below its 52-week high of $8.31, though it has recovered slightly (+5.7%) in the 30-day window. The company remains unprofitable with a net loss of $-11.1M in the latest quarter despite +13.6% annual revenue growth, so the repeated insider buying occurs against a backdrop of negative earnings and significant recent price weakness. The pattern of repeated small purchases at depressed prices warrants investor attention, particularly given the unprofitable operating context and volatility.
EVP R&D Raheja buys 3,376 shares of SGHT at $3.89; stock down -55.5% from 52-week high, company unprofitable
Raheja Manohar K., EVP of Research & Development, purchased 3,376 shares at $3.89 on 2024-12-03, adding to a position that has grown to 106,000 shares post-transaction. This marks his third open-market purchase at SGHT within two weeks—he also bought on 2024-11-29 and 2024-11-19. The timing context is notable: the stock is currently trading at $3.70, representing -55.5% from its 52-week high and -41.7% over the past 90 days. Sight Sciences remains unprofitable (net income $-11.1M against quarterly revenue of $20.2M) despite 13.6% annual revenue growth, a fundamental tension that warrants attention from investors tracking the path to profitability. The repeated buying pattern within a short window, combined with the severe drawdown from recent highs, is the key signal for monitoring.
EVP R&D Raheja Manohar K. bought 4,624 shares of SGHT at $3.99; stock -53.6% from 52-week high, company unprofitable.
Raheja Manohar K., EVP of Research & Development, purchased 4,624 shares at $3.99 on 2024-11-29, adding to holdings of 102,624 shares post-transaction. The purchase occurs in a context of pronounced stock weakness: the current price of $3.86 sits at -53.6% from the 52-week high of $8.31, and the stock has declined -25.9% over the past 30 days and -39.8% over 90 days. Sight Sciences remains unprofitable (net income of $-11.1M on quarterly revenue of $20.2M), though the company posted +13.6% annual revenue growth. This is Raheja's second consecutive buy within the filing window (a prior buy on 2024-11-19 and another on 2024-12-03), but his cross-ticker track record shows only 2 prior open-market buys, with neither exhibiting positive 90-day outcomes. The outcomes of these same-ticker recent buys are not yet measurable.
EVP R&D Raheja buys 2,000 SGHT shares at $3.70 amid -54.8% 52-week decline; stock at $3.76.
Raheja Manohar K., EVP of Research & Development at Sight Sciences, purchased 2,000 shares at $3.70 on 2024-11-19, adding to his 96,000 existing holdings. The purchase occurs while the stock is trading near its 52-week low relative to the high of $8.31 (down 54.8%), having declined 33.4% over the prior 30 days and 44.4% over 90 days. The company remains unprofitable on a full-year basis with net income of $-11.1M against quarterly revenue of $20.2M, though it has achieved 13.6% annual revenue growth. This small open-market accumulation by an R&D executive provides limited inference about insider conviction given the modest size relative to existing holdings and the lack of coordinated buying signals from other insiders.
